Multisociety Jordan National Dyslipidemia Management<\/p>\n
Clinical Protocols Initiative<\/p>\n
A Collaborative Program of Nine Jordanian Medical Societies
\nCoordinated by the Jordan Cardiac Society (JCS)<\/p>\n
\u2e3b<\/p>\n
Participating Societies<\/p>\n
\u2022\u2060 \u2060Jordanian Cardiac Society (JCS)
\n\u2022\u2060 \u2060Jordan Atherosclerosis Society (JAS)
\n\u2022\u2060 \u2060Jordan Society of General Practitioners (JSGP)
\n\u2022\u2060 \u2060Jordan Society of Internal Medicine (JSIM)
\n\u2022\u2060 \u2060Jordan Society of Nephrology (JSN)
\n\u2022\u2060 \u2060Jordan Society of Family Medicine (JSFM)
\n\u2022\u2060 \u2060Jordan Emergency Medicine Society (JEMS)
\n\u2022\u2060 \u2060Jordan Endocrine and Diabetes Society (JEDS)
\n\u2022\u2060 \u2060Jordan Nutrition Society (JNS)<\/p>\n
Core Principle<\/p>\n
Understanding ApoB in Clinical Practice<\/p>\n
Cholesterol and triglycerides are fatty substances that do not dissolve in the blood, which is water-based. To circulate in the bloodstream they must be transported inside protein particles known as lipoproteins.<\/p>\n
Apolipoprotein B (ApoB) is the structural protein present on all atherogenic lipoprotein particles, including:<\/p>\n
\u2022\u2060 \u2060LDL
\n\u2022\u2060 \u2060VLDL
\n\u2022\u2060 \u2060IDL
\n\u2022\u2060 \u2060Remnant particles
\n\u2022\u2060 \u2060Lipoprotein(a)<\/p>\n
Each atherogenic particle contains one ApoB molecule. Therefore, measuring ApoB reflects the total number of atherogenic particles circulating in the blood.<\/p>\n
These particles penetrate the arterial wall and promote the development of atherosclerosis.<\/p>\n
Atherosclerosis is driven by ApoB-containing lipoproteins, particularly LDL particles.<\/p>\n
Clinical evidence consistently shows:<\/p>\n
\u201cThe lower the LDL, the lower the cardiovascular risk.\u201d<\/p>\n
LDL cholesterol therefore remains the primary therapeutic target.<\/p>\n
1.\u2060 \u2060Lipid Screening<\/p>\n
Screening should begin:<\/p>\n
\u2022\u2060 \u2060From age \u22655 years if there is a family history of premature ASCVD
\n\u2022\u2060 \u2060From age \u22652 years when severe homozygous familial hypercholesterolemia is suspected<\/p>\n
Minimum Tests for Cardiovascular Risk Assessment<\/p>\n
Routine baseline evaluation should include:<\/p>\n
\u2022\u2060 \u2060Blood pressure measurement
\n\u2022\u2060 \u2060Lipid panel (Total cholesterol, LDL, HDL, triglycerides, non-HDL cholesterol)
\n\u2022\u2060 \u2060HbA1c or fasting glucose
\n\u2022\u2060 \u2060Body mass index and waist circumference
\n\u2022\u2060 \u2060Smoking status<\/p>\n
Optional Tests (Risk-Based)<\/p>\n
\u2022\u2060 \u2060Lp(a) \u2013 once in a lifetime, particularly with family history of premature cardiovascular disease
\n\u2022\u2060 \u2060ApoB \u2013 useful when triglycerides are elevated or when cardiovascular risk appears higher than expected<\/p>\n
Fasting is not routinely required.<\/p>\n
Fasting is recommended only when triglycerides exceed 400 mg\/dL.<\/p>\n
2.\u2060 \u2060Cardiovascular Risk Stratification<\/p>\n
Accurate cardiovascular risk assessment is the cornerstone of preventive cardiology.<\/p>\n
Risk stratification determines:<\/p>\n
\u2022\u2060 \u2060The intensity of lipid-lowering therapy
\n\u2022\u2060 \u2060Blood pressure targets
\n\u2022\u2060 \u2060Timing of combination therapy
\n\u2022\u2060 \u2060Frequency of follow-up<\/p>\n
The higher the vascular risk, the earlier and more intensive treatment should be initiated.<\/p>\n
Two Approaches to Risk Estimation<\/p>\n
1.\u2060 \u2060Risk Calculators<\/p>\n
Risk calculators estimate 10-year cardiovascular risk.<\/p>\n
European models:<\/p>\n
\u2022\u2060 \u2060SCORE2
\n\u2022\u2060 \u2060SCORE2-OP<\/p>\n
American models:<\/p>\n
\u2022\u2060 \u2060PREVENT
\n\u2022\u2060 \u2060ASCVD Risk Estimator Plus<\/p>\n
2.\u2060 \u2060Clinical Risk Classification<\/p>\n
In high-burden regions, a clinical risk-based classification may be more practical.<\/p>\n
Low Risk<\/p>\n
\u2022\u2060 \u2060No major cardiovascular risk factors
\n\u2022\u2060 \u2060No diabetes
\n\u2022\u2060 \u2060No CKD
\n\u2022\u2060 \u2060No vascular disease<\/p>\n
LDL-C Target: <116 mg\/dL<\/p>\n
Lifestyle measures are usually sufficient.<\/p>\n
Moderate Risk<\/p>\n
\u2022\u2060 \u2060One major risk factor
\n(hypertension, smoking, dyslipidemia, obesity, strong family history)<\/p>\n
LDL-C Target: <100 mg\/dL<\/p>\n
Pharmacologic therapy should be considered if lifestyle measures fail.<\/p>\n
High Risk<\/p>\n
\u2022\u2060 \u2060\u22652 major risk factors
\n\u2022\u2060 \u2060Diabetes without organ damage (<10 years)
\n\u2022\u2060 \u2060LDL \u2265190 mg\/dL
\n\u2022\u2060 \u2060CKD (eGFR 30\u201359)<\/p>\n
LDL-C Target: <70 mg\/dL<\/p>\n
Combination lipid-lowering therapy is often required.<\/p>\n
Very High Risk<\/p>\n
\u2022\u2060 \u2060Established ASCVD
\n\u2022\u2060 \u2060Complicated diabetes
\n\u2022\u2060 \u2060Severe CKD (eGFR <30)
\n\u2022\u2060 \u2060Polyvascular disease<\/p>\n
LDL-C Target: <55 mg\/dL<\/p>\n
Extreme Risk<\/p>\n
\u2022\u2060 \u2060Recurrent ASCVD events
\n\u2022\u2060 \u2060Progressive vascular disease despite optimal therapy<\/p>\n
LDL-C Target: <40 mg\/dL<\/p>\n
Advanced therapies such as PCSK9 inhibitors should be considered early.<\/p>\n
Regional Considerations<\/p>\n
Cardiovascular disease in our region often occurs earlier and more aggressively due to:<\/p>\n
\u2022\u2060 \u2060Low public awareness of preventive cardiology
\n\u2022\u2060 \u2060Delayed clinical presentation
\n\u2022\u2060 \u2060Limited structured screening programs
\n\u2022\u2060 \u2060High prevalence of diabetes, obesity and smoking
\n\u2022\u2060 \u2060Restricted access to advanced therapies
\n\u2022\u2060 \u2060Fragmented follow-up systems<\/p>\n
Therefore, earlier treatment intensification may be appropriate.<\/p>\n
3.\u2060 \u2060Treatment Strategy<\/p>\n
Step 1 \u2013 Lifestyle Measures<\/p>\n
Recommended for all patients:<\/p>\n
\u2022\u2060 \u2060Mediterranean-style diet
\n\u2022\u2060 \u2060Reduced saturated fats
\n\u2022\u2060 \u2060Increased fiber intake
\n\u2022\u2060 \u2060Regular physical activity
\n\u2022\u2060 \u2060Weight control
\n\u2022\u2060 \u2060Smoking cessation
\n\u2022\u2060 \u2060Avoid excessive alcohol intake<\/p>\n
Step 2 \u2013 Risk-Based Lipid Management<\/p>\n
Step 0 \u2013 Define LDL Target<\/p>\n
High Risk \u2192 <70 mg\/dL<\/p>\n
Very High Risk \u2192 <55 mg\/dL<\/p>\n
Extreme Risk \u2192 <40 mg\/dL<\/p>\n
Stepwise Treatment<\/p>\n
1\ufe0f\u20e3 Start High-Intensity Statin<\/p>\n
\u2022\u2060 \u2060Atorvastatin 40\u201380 mg
\n\u2022\u2060 \u2060Rosuvastatin 20\u201340 mg<\/p>\n
Reassess LDL after 4 weeks.<\/p>\n
2\ufe0f\u20e3 If LDL remains above target<\/p>\n
Add Ezetimibe<\/p>\n
Reassess after 4 weeks.<\/p>\n
3\ufe0f\u20e3 If LDL still above goal<\/p>\n
Consider advanced therapies.<\/p>\n
Advanced Therapies<\/p>\n
PCSK9 inhibitors<\/p>\n
Indicated particularly in:<\/p>\n
\u2022\u2060 \u2060Extreme risk
\n\u2022\u2060 \u2060Recurrent ASCVD events
\n\u2022\u2060 \u2060Multivessel coronary disease
\n\u2022\u2060 \u2060Diabetes with ASCVD<\/p>\n
Major outcome trials:<\/p>\n
\u2022\u2060 \u2060FOURIER
\n\u2022\u2060 \u2060ODYSSEY<\/p>\n
Alternative Therapy<\/p>\n
Inclisiran<\/p>\n
Dosing schedule:<\/p>\n
\u2022\u2060 \u2060Day 0
\n\u2022\u2060 \u2060Month 3
\n\u2022\u2060 \u2060Every 6 months thereafter<\/p>\n
LDL reduction \u2248 50%<\/p>\n
Statin Intolerance<\/p>\n
Consider:<\/p>\n
\u2022\u2060 \u2060Bempedoic acid
\n(\u224820% LDL reduction)<\/p>\n
4.\u2060 \u2060Triglycerides<\/p>\n
If TG >150 mg\/dL<\/p>\n
\u2022\u2060 \u2060Intensify lifestyle
\n\u2022\u2060 \u2060Optimize metabolic control<\/p>\n
If TG \u2265500 mg\/dL<\/p>\n
\u2022\u2060 \u2060Prevent pancreatitis
\n\u2022\u2060 \u2060Consider fibrates<\/p>\n
5.\u2060 \u2060Residual Risk<\/p>\n
If LDL targets are achieved but cardiovascular risk persists, evaluate:<\/p>\n
\u2022\u2060 \u2060ApoB
\n\u2022\u2060 \u2060Triglycerides
\n\u2022\u2060 \u2060Lipoprotein(a)
\n\u2022\u2060 \u2060Metabolic risk factors<\/p>\n
LDL reduction should always be addressed before additional lipid abnormalities.<\/p>\n
Omega-3 Therapy (Icosapent Ethyl)<\/p>\n
ACC recommends icosapent ethyl (EPA) in statin-treated patients with:<\/p>\n
\u2022\u2060 \u2060Triglycerides 135\u2013499 mg\/dL
\n\u2022\u2060 \u2060High ASCVD risk<\/p>\n
Clinical trials showed a small increase in atrial fibrillation:<\/p>\n
\u2022\u2060 \u20605.3% vs 3.9%
\nAbsolute increase \u2248 1.4%<\/p>\n
Use caution in patients with:<\/p>\n
\u2022\u2060 \u2060Prior AF
\n\u2022\u2060 \u2060Enlarged left atrium
\n\u2022\u2060 \u2060Multiple AF risk factors<\/p>\n
Statin Safety<\/p>\n
A large Lancet meta-analysis (2026) involving more than 123,000 patients found:<\/p>\n
\u2022\u2060 \u2060No strong evidence that statins cause most commonly reported side effects.<\/p>\n
The only consistently confirmed adverse effect was:<\/p>\n
\u2022\u2060 \u2060Mild elevation of liver enzymes.<\/p>\n
Many muscle symptoms reported in practice are not directly caused by statins.<\/p>\n
Statin-Associated Muscle Symptoms<\/p>\n
True statin myopathy is rare and usually mild.<\/p>\n
If symptoms occur:<\/p>\n
\u2022\u2060 \u2060Check creatine kinase (CK)
\n\u2022\u2060 \u2060Exclude secondary causes such as hypothyroidism or drug interactions<\/p>\n
CK Interpretation<\/p>\n
CK <4\u00d7 ULN
\n\u2192 Continue therapy or briefly pause and reassess<\/p>\n
CK \u226510\u00d7 ULN
\n\u2192 Consistent with myopathy; discontinue statin<\/p>\n
Clinical Principle<\/p>\n
The cardiovascular benefits of statins greatly outweigh the small risk of muscle toxicity.<\/p>\n
References<\/p>\n
ESC \/ EAS Dyslipidaemia Guidelines <\/p>\n ACC Clinical Guidance<\/p>\n
\nhttps:\/\/www.escardio.org\/Guidelines\/Clinical-Practice-Guidelines\/Dyslipidaemias<\/a><\/p>\n